CELONEX PHARMACEUTICALS AND CELONEX LIFE SCIENCE ARE LOCATED IN EDMONTON, ALBERTA.

The Life Science division specializes in the development of new technologies for fast, ultra sensitive, and high-throughput genomics and proteomics analysis. Celonex has developed a unique new microarray platform in CeramiChip™. This new platform can be used for both DNA and protein microarray, and clearly surpasses glass-based platforms in many respects. Using its unique microarray system, Celonex is the only company worldwide that manufactures and commercializes various DNA microarrays for functional genomic studies of many important human viruses, such as HIV1/2, human herpes viruses (HHV1-8), etc. Celonex has also developed a non-enzymatic DNA amplification technology that can efficiently intensify the detection signals on different genomics and proteomics platforms. It can also be used for ultra sensitive detection in other molecular or immunochemical assays. Furthermore, Celonex is a fast expanding company that places an emphasis on proteomics and production of specific monoclonal antibodies against the entire human proteins.

The Celonex Pharmaceuticals division has recently been created to discover new drug targets and to develop more efficient drug delivery systems, using Celonex’s advanced genomics and proteomics technologies and information. Our current focus is on hypertension and its associated diseases, such as chronic high blood pressure, heart attack, stroke, kidney failure, glaucoma, diabetes, etc. In the hope of finding new drug targets for such diseases, Celonex continues to discover the structure of a small molecule referred to as parathyroid hypertensive factor (PHF). This molecule has been clinically linked to high blood pressure and has also been shown to directly cause hypertension in a model organism.

Celonex is owned and managed by Triple Five®.